Global Sleep Aid Market Projected at $48.5 Billion in 2025, Growing at a 6.1% CAGR

Sleep aid market was valued at $48.5 billion in 2025 and is growing at a CAGR of 6.1% during the forecast period (2026-2035). Growing recognition of sleep disorders, coupled with rising stress levels worldwide, is fueling the demand for more effective insomnia treatments, thereby driving the expansion of the sleep aid market. In line with this trend, pharmaceutical companies are increasingly focusing on developing novel therapies that target the underlying mechanisms of sleep regulation. For instance, in August 2025, Eisai launched its in-house developed anti-insomnia drug DAYVIGO (lemborexant) in China for treating adults with insomnia, impacting sleep onset and maintenance. DAYVIGO is a dual orexin receptor antagonist, acting by competitively binding to OX1R and OX2R receptors, regulating sleep-wake rhythm differently than conventional treatments like benzodiazepines. This drug may enhance sleep onset and maintenance by inhibiting wakefulness. Insomnia affects 15% of adults in China, with around 172.5 million individuals affected, highlighting the increasing need for novel treatment solutions beyond current options.

Browse the full report description of “Sleep Aid Market Size, Share & Trends Analysis Report by Sleep Disorder (Insomnia, Sleep Apnea, Narcolepsy, Sleep Walking, and Restless Legs Syndrome), By Products (Sleep Laboratories Services, Specialty Mattresses and Pillows, Medications, and Sleep Apnea Devices), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/sleep-aid-market

Innovators Driving Growth and Transformation in the Sleep Aid Market

Leading pharmaceutical companies, including GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, and Sanofi, are driving significant growth in the sleep aid market through innovation in both therapies and digital health solutions. By developing advanced treatments, such as mechanism-based insomnia drugs, and integrating technologies like telemedicine, AI-powered monitoring, and electronic health records, these innovators are improving treatment outcomes and patient engagement. Their strategic focus on combining novel therapies with digital solutions is reshaping the market landscape, expanding access to effective sleep aids, and supporting the transition toward personalized, technology-enabled healthcare delivery.

• In June 2025, Simcere Pharmaceutical announced the approval of QUVIVIQ (Daridorexant Hydrochloride Tablets) by the National Medical Products Administration for treating adult insomnia characterized by difficulty in falling asleep and/or maintaining sleep. The approval is based on a Phase III clinical trial (NCT06010693) led by Professor Yuping Wang, involving 206 patients. QUVIVIQ demonstrated significant efficacy in improving latency to persistent sleep (LPS) and wake after sleep onset (WASO), as well as increasing subjective total sleep time (sTST) and sleep quality, with favorable safety profiles. Statistically significant improvements were noted in sleep onset and maintenance, particularly in the latter part of the night.
• In October 2024, Neurovalens launched Modius Sleep, an FDA-cleared medical device designed for the treatment of chronic insomnia in adults. This portable, battery-operated neurostimulation device is worn on the head for 30 minutes nightly and delivers low-level electrical pulses to the vestibular nerve, targeting brain areas linked to circadian rhythms and sleep patterns. It features two self-adhesive electrode pads placed behind the ears, allowing users to adjust the pulse intensity.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Sleep Disorder
  • By Products
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Sleep Aid Market Report Segment

By Sleep Disorder

• Insomnia
• Sleep Apnea
• Narcolepsy
• Sleep Walking
• Restless Legs Syndrome

By Products

• Sleep Laboratories Services
• Specialty Mattresses and Pillows
• Medications
  • Prescription Drugs
  • OTC Drugs
  • Herbal Drugs
• Sleep Apnea Devices
  • Diagnostics Devices
  • Therapeutic Devices

Global Sleep Aid Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/sleep-aid-market